Poly(ADP-Ribose) polymerase (PARP) inhibitors result in impressive clinical activity in patients with germline BRCA1 and BRCA2 (BRCA1/2) mutant cancers through a single agent therapeutic strategy based on the concept of tumor-specific synthetic lethality [1-5]. This evidence concerns the gene BRCA2 and cancer.